SlideShare una empresa de Scribd logo
1 de 16
Shakul Hameed
QOS in Publishing Prospective
Introduction
  QOS is a document that contains outline summary (or)     
    overview of Module 3 Information.
 As per ICH guidelines the QOS document should not 
include any data or justification that was already in 
module 3 or any other parts of the CTD.
 The QOS normally should not exceed 40 pages of text 
excluding tables and figures.
 For biologic products there might be a chances to exceed 
up to 80 pages.
QOS in eCTD
Consideration for preparation of QOS Using eCTD 
formats
 Granularity considerations 
  Hyperlink practices between QOS and Module 3 
Documents 
  Attributes, leaf titles and eCTD file names
 Management of multiple drug substance and drug 
product sections 
 Life Cycle Operation for QOS
Granularity for QOS
 The ICH Guidance “Granularity Document Annex to M4: 
Organization of the CTD” outlines three levels of allowed 
granularity for QOS. 
 Companies are using these three variety of approaches for 
the presentation of the QOS. They are 
 The single QOS file 
 The mid-range QOS 
 The Maximum QOS 
Granularity for QOS
 The single QOS file
ICH allows the submission of a single document under Module 2.3
Quality Overall Summary which includes the sections 2.3 Introduction,
2.3.S, 2.3.P and 2.3.R.
 The mid-range granularity QOS
According to ICH, the mid-range granularity consists of separate
documents under each of the following heading sections:
2.3 Introduction
2.3.Drug Substance
2.3.Drug Product
2.3.Appendices
2.3.Regional
Granularity for QOS
The Maximum Granularity QOS
 The maximum granularity of the QOS depends on
company’s business practice and strategy.
 This maximum granularity approach can be beneficial if
new data and multiple changes are anticipated after
approval of the product. So that Authors need only to
update the sections that have changed, reducing the
amount of reviewed information that would be resubmitted.
Granularity for QOS
2.3 Introduction
2.3.S Drug Substance
2.3.S.1 General Information
2.3.S.2 Manufacture
2.3.S.3 Characterization
2.3.S.4 Control of Drug Substance
2.3.S.5 Reference Standard or Materials
2.3.S.6 Container Closure
2.3.S.7 Stability
2.3.P Drug Product
2.3.P.1 Description
2.3.P.2 Pharmaceutical Development
2.3.P.3 Manufacture
2.3.P.4 Control of Excipients
2.3.P.5 Control of Drug Product
2.3.P.6 Reference Standard or Material
2.3.P.7 Container Closure
2.3.P.8 Stability
2.3.A Appendices
2.3.R Regional Information
Hyperlink Practices for QOS
 Hyperlinks serve as an aid to the reviewer to review the
submission.
 Cross references to specific items within section
documents (e.g. tables, figures, etc.) or destinations
outside of Module 3 could be hyperlinked.
 Some companies do not include any hyperlinks in the
QOS, relying solely on references to Module 3 section
numbers.
Attributes for QOS
 The designation of attributes for the Module 2.3 QOS is
directly influenced by the eCTD build.
 Some build tools will allow attributes for the Module 2.3
QOS and Module 3 to be entered separately, thereby
providing the flexibility to designate different attributes
between the two Modules.
 Alternatively, some build tools will automatically duplicate
the designated Module 3 attributes for the Module 2.3
QOS.
Leaf Titles and eCTD file names for QOS
 Whether the Module 2.3 QOS is provided as a single
document or a series of multiple documents, the leaf title(s)
should be descriptive, clear and allow the reviewer to be
able to identify the document.
 eCTD file name for QOS companies are asked to follow
ICH eCTD_Specification_v3_2_2.pdf document.
eg : introduction-qos.pdf
drug-substance.pdf
drug-product.pdf
Management of Multiple Drug Substances and
Drug Products
 2.3 QOS depends on the company’s desired business
practices and the limitations of the software tools.
Single QOS document
 Using a single document for Module 2.3 QOS regardless of
the number of DS and DP sections in Module 3.
Multiple Drug Substance Sections with Common
Information
 If the application contains multiple 3.2.S sections with
shared information, e.g. DS made in multiple manufacturing
sites, a separate pdf can be provided under the relevant
2.3.S granular sections
Multiple Drug Substance Sections with Common
Information
Multiple Drug Substance Sections in Combination
Product
Table following table is an example of a combination product where
there are different 3.2.S drug substance Sections and one 3.2.P drug
product section.
Multiple Drug Product Sections in Combination
Product
 There are two examples for Multiple drug product sections
in combination product.
 The first example provides maximum granularity for ease of
review and life cycle management.
Multiple Drug Product Sections in Combination
Product
 The second example provides a single pdf document for all
drug product and the entire document is updated
regardless of what new information is included.
Lifecycle Management for QOS
 Generally two life cycle operation attributes are used for
QOS document.
New
Replace

Más contenido relacionado

La actualidad más candente

REGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIES
REGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIESREGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIES
REGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIES
Dhruvi Panchal
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxREGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
BharatRRDesai
 
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATESQUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
vasanthi chodavarapu
 

La actualidad más candente (20)

Supac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormSupac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage Form
 
Ipqc during packaging operation.
Ipqc during packaging operation.Ipqc during packaging operation.
Ipqc during packaging operation.
 
CDER
CDERCDER
CDER
 
Guidelines gdp
Guidelines gdpGuidelines gdp
Guidelines gdp
 
Cmc, post approval and regulation
Cmc, post approval and regulationCmc, post approval and regulation
Cmc, post approval and regulation
 
Investigation of medicinal product dossier (IMPD) and investigational brochur...
Investigation of medicinal product dossier (IMPD) and investigational brochur...Investigation of medicinal product dossier (IMPD) and investigational brochur...
Investigation of medicinal product dossier (IMPD) and investigational brochur...
 
SUPAC, BACPAC, Post Marketing Surveillance
SUPAC, BACPAC, Post Marketing SurveillanceSUPAC, BACPAC, Post Marketing Surveillance
SUPAC, BACPAC, Post Marketing Surveillance
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIES
REGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIESREGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIES
REGULATORY REQUIREMENTS OF EU, MHRA, TGA AND RoW COUNTRIES
 
Batch Review And Batch Release.pptx
Batch Review And Batch Release.pptxBatch Review And Batch Release.pptx
Batch Review And Batch Release.pptx
 
Combinational products & medical devices
Combinational products & medical devicesCombinational products & medical devices
Combinational products & medical devices
 
FDA Warning Letter
FDA Warning LetterFDA Warning Letter
FDA Warning Letter
 
Quality by design
Quality by designQuality by design
Quality by design
 
CMC
CMCCMC
CMC
 
Documentation in Pharmaceutical Industry Part II
Documentation in Pharmaceutical Industry Part  II Documentation in Pharmaceutical Industry Part  II
Documentation in Pharmaceutical Industry Part II
 
Developing clinical trial protocols,institutional review board(irb,iec),infor...
Developing clinical trial protocols,institutional review board(irb,iec),infor...Developing clinical trial protocols,institutional review board(irb,iec),infor...
Developing clinical trial protocols,institutional review board(irb,iec),infor...
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICE
 
ANDA APPROVAL PROCESS.pptx
ANDA APPROVAL PROCESS.pptxANDA APPROVAL PROCESS.pptx
ANDA APPROVAL PROCESS.pptx
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxREGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
 
Documentation in Pharmaceutical Industry Part I
Documentation in Pharmaceutical Industry Part I Documentation in Pharmaceutical Industry Part I
Documentation in Pharmaceutical Industry Part I
 
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATESQUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
QUALITY SYSTEM REQUIREMENTS FOR NATIONAL GMP INSPECTORATES
 

Destacado

Scale up and post approval changes(supac)
Scale up and post approval changes(supac)Scale up and post approval changes(supac)
Scale up and post approval changes(supac)
bdvfgbdhg
 

Destacado (9)

Four Levels of In-Vitro-In-Vivo Correlation
Four Levels of In-Vitro-In-Vivo CorrelationFour Levels of In-Vitro-In-Vivo Correlation
Four Levels of In-Vitro-In-Vivo Correlation
 
Stability studies of drug ICH Q1
Stability studies of drug ICH Q1 Stability studies of drug ICH Q1
Stability studies of drug ICH Q1
 
Snda
SndaSnda
Snda
 
Scale up and post approval changes(supac)
Scale up and post approval changes(supac)Scale up and post approval changes(supac)
Scale up and post approval changes(supac)
 
Granulation process and types of granulators
Granulation process and types of granulatorsGranulation process and types of granulators
Granulation process and types of granulators
 
Tablet Formulation Technology
Tablet Formulation TechnologyTablet Formulation Technology
Tablet Formulation Technology
 
Quality by Design : Quality Target Product Profile & Critical Quality Attrib...
Quality by Design : Quality Target Product  Profile & Critical Quality Attrib...Quality by Design : Quality Target Product  Profile & Critical Quality Attrib...
Quality by Design : Quality Target Product Profile & Critical Quality Attrib...
 
Tablet types and Excipients
Tablet  types and ExcipientsTablet  types and Excipients
Tablet types and Excipients
 
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
 

Similar a QOS In Publishing Prospective

Driving Innovation in Healthcare with Containers and Docker
Driving Innovation in Healthcare with Containers and DockerDriving Innovation in Healthcare with Containers and Docker
Driving Innovation in Healthcare with Containers and Docker
CitiusTech
 
Modbus application protocol_v1_1b_2
Modbus application protocol_v1_1b_2Modbus application protocol_v1_1b_2
Modbus application protocol_v1_1b_2
Ashar Saleem
 
PharmaLedger framework architecture
PharmaLedger framework architecturePharmaLedger framework architecture
PharmaLedger framework architecture
PharmaLedger
 
Paper MIE2016 from Proceedings pags 122-126
Paper MIE2016 from Proceedings pags 122-126Paper MIE2016 from Proceedings pags 122-126
Paper MIE2016 from Proceedings pags 122-126
vilaltajo
 
121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx
TridevSastri1
 
Quest Diagnostics -- Test Compendium Framework for eDOS
Quest Diagnostics -- Test Compendium Framework for eDOSQuest Diagnostics -- Test Compendium Framework for eDOS
Quest Diagnostics -- Test Compendium Framework for eDOS
Keith Drake
 
TechDoc - WMB - Administration - Logs
TechDoc - WMB - Administration - LogsTechDoc - WMB - Administration - Logs
TechDoc - WMB - Administration - Logs
Glen Brumbaugh
 
Fuzzy Based Algorithm for Cloud Resource Management and Task Scheduling
Fuzzy Based Algorithm for Cloud Resource Management and Task SchedulingFuzzy Based Algorithm for Cloud Resource Management and Task Scheduling
Fuzzy Based Algorithm for Cloud Resource Management and Task Scheduling
ijtsrd
 

Similar a QOS In Publishing Prospective (20)

PharmaLedger – Blockchain platform research
PharmaLedger – Blockchain platform researchPharmaLedger – Blockchain platform research
PharmaLedger – Blockchain platform research
 
Driving Innovation in Healthcare with Containers and Docker
Driving Innovation in Healthcare with Containers and DockerDriving Innovation in Healthcare with Containers and Docker
Driving Innovation in Healthcare with Containers and Docker
 
Modbus application protocol_v1_1b_2
Modbus application protocol_v1_1b_2Modbus application protocol_v1_1b_2
Modbus application protocol_v1_1b_2
 
A DDS-Based Scalable and Reconfigurable Framework for Cyber-Physical Systems
A DDS-Based Scalable and Reconfigurable Framework for Cyber-Physical SystemsA DDS-Based Scalable and Reconfigurable Framework for Cyber-Physical Systems
A DDS-Based Scalable and Reconfigurable Framework for Cyber-Physical Systems
 
PharmaLedger framework architecture
PharmaLedger framework architecturePharmaLedger framework architecture
PharmaLedger framework architecture
 
Product Serialization using Blockchain
Product Serialization using BlockchainProduct Serialization using Blockchain
Product Serialization using Blockchain
 
Paper MIE2016 from Proceedings pags 122-126
Paper MIE2016 from Proceedings pags 122-126Paper MIE2016 from Proceedings pags 122-126
Paper MIE2016 from Proceedings pags 122-126
 
Exchanging the Status between Clients of Geospatial Web Services and GIS appl...
Exchanging the Status between Clients of Geospatial Web Services and GIS appl...Exchanging the Status between Clients of Geospatial Web Services and GIS appl...
Exchanging the Status between Clients of Geospatial Web Services and GIS appl...
 
Chemread – a chemical informant
Chemread – a chemical informantChemread – a chemical informant
Chemread – a chemical informant
 
iEHR.eu IHIC 2012 Paper
iEHR.eu IHIC 2012 PaperiEHR.eu IHIC 2012 Paper
iEHR.eu IHIC 2012 Paper
 
PharmaLedger – Blockchain platform modifications and interoperability
PharmaLedger – Blockchain platform modifications and interoperabilityPharmaLedger – Blockchain platform modifications and interoperability
PharmaLedger – Blockchain platform modifications and interoperability
 
121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx
 
How document templates can facilitate or prohibit multipurpose documents
How document templates can facilitate or prohibit multipurpose documentsHow document templates can facilitate or prohibit multipurpose documents
How document templates can facilitate or prohibit multipurpose documents
 
Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD Submissions
 
Quest Diagnostics -- Test Compendium Framework for eDOS
Quest Diagnostics -- Test Compendium Framework for eDOSQuest Diagnostics -- Test Compendium Framework for eDOS
Quest Diagnostics -- Test Compendium Framework for eDOS
 
AtoZ about TYPO3 v8 CMS
AtoZ about TYPO3 v8 CMSAtoZ about TYPO3 v8 CMS
AtoZ about TYPO3 v8 CMS
 
TechDoc - WMB - Administration - Logs
TechDoc - WMB - Administration - LogsTechDoc - WMB - Administration - Logs
TechDoc - WMB - Administration - Logs
 
S1000D - An Overview
S1000D - An OverviewS1000D - An Overview
S1000D - An Overview
 
Fuzzy Based Algorithm for Cloud Resource Management and Task Scheduling
Fuzzy Based Algorithm for Cloud Resource Management and Task SchedulingFuzzy Based Algorithm for Cloud Resource Management and Task Scheduling
Fuzzy Based Algorithm for Cloud Resource Management and Task Scheduling
 

QOS In Publishing Prospective

  • 1. Shakul Hameed QOS in Publishing Prospective
  • 3. QOS in eCTD Consideration for preparation of QOS Using eCTD  formats  Granularity considerations    Hyperlink practices between QOS and Module 3  Documents    Attributes, leaf titles and eCTD file names  Management of multiple drug substance and drug  product sections   Life Cycle Operation for QOS
  • 4. Granularity for QOS  The ICH Guidance “Granularity Document Annex to M4:  Organization of the CTD” outlines three levels of allowed  granularity for QOS.   Companies are using these three variety of approaches for  the presentation of the QOS. They are   The single QOS file   The mid-range QOS   The Maximum QOS 
  • 5. Granularity for QOS  The single QOS file ICH allows the submission of a single document under Module 2.3 Quality Overall Summary which includes the sections 2.3 Introduction, 2.3.S, 2.3.P and 2.3.R.  The mid-range granularity QOS According to ICH, the mid-range granularity consists of separate documents under each of the following heading sections: 2.3 Introduction 2.3.Drug Substance 2.3.Drug Product 2.3.Appendices 2.3.Regional
  • 6. Granularity for QOS The Maximum Granularity QOS  The maximum granularity of the QOS depends on company’s business practice and strategy.  This maximum granularity approach can be beneficial if new data and multiple changes are anticipated after approval of the product. So that Authors need only to update the sections that have changed, reducing the amount of reviewed information that would be resubmitted.
  • 7. Granularity for QOS 2.3 Introduction 2.3.S Drug Substance 2.3.S.1 General Information 2.3.S.2 Manufacture 2.3.S.3 Characterization 2.3.S.4 Control of Drug Substance 2.3.S.5 Reference Standard or Materials 2.3.S.6 Container Closure 2.3.S.7 Stability 2.3.P Drug Product 2.3.P.1 Description 2.3.P.2 Pharmaceutical Development 2.3.P.3 Manufacture 2.3.P.4 Control of Excipients 2.3.P.5 Control of Drug Product 2.3.P.6 Reference Standard or Material 2.3.P.7 Container Closure 2.3.P.8 Stability 2.3.A Appendices 2.3.R Regional Information
  • 8. Hyperlink Practices for QOS  Hyperlinks serve as an aid to the reviewer to review the submission.  Cross references to specific items within section documents (e.g. tables, figures, etc.) or destinations outside of Module 3 could be hyperlinked.  Some companies do not include any hyperlinks in the QOS, relying solely on references to Module 3 section numbers.
  • 9. Attributes for QOS  The designation of attributes for the Module 2.3 QOS is directly influenced by the eCTD build.  Some build tools will allow attributes for the Module 2.3 QOS and Module 3 to be entered separately, thereby providing the flexibility to designate different attributes between the two Modules.  Alternatively, some build tools will automatically duplicate the designated Module 3 attributes for the Module 2.3 QOS.
  • 10. Leaf Titles and eCTD file names for QOS  Whether the Module 2.3 QOS is provided as a single document or a series of multiple documents, the leaf title(s) should be descriptive, clear and allow the reviewer to be able to identify the document.  eCTD file name for QOS companies are asked to follow ICH eCTD_Specification_v3_2_2.pdf document. eg : introduction-qos.pdf drug-substance.pdf drug-product.pdf
  • 11. Management of Multiple Drug Substances and Drug Products  2.3 QOS depends on the company’s desired business practices and the limitations of the software tools. Single QOS document  Using a single document for Module 2.3 QOS regardless of the number of DS and DP sections in Module 3. Multiple Drug Substance Sections with Common Information  If the application contains multiple 3.2.S sections with shared information, e.g. DS made in multiple manufacturing sites, a separate pdf can be provided under the relevant 2.3.S granular sections
  • 12. Multiple Drug Substance Sections with Common Information
  • 13. Multiple Drug Substance Sections in Combination Product Table following table is an example of a combination product where there are different 3.2.S drug substance Sections and one 3.2.P drug product section.
  • 14. Multiple Drug Product Sections in Combination Product  There are two examples for Multiple drug product sections in combination product.  The first example provides maximum granularity for ease of review and life cycle management.
  • 15. Multiple Drug Product Sections in Combination Product  The second example provides a single pdf document for all drug product and the entire document is updated regardless of what new information is included.
  • 16. Lifecycle Management for QOS  Generally two life cycle operation attributes are used for QOS document. New Replace